News for hackers. Stuff that matters.
Re:Covid-19’s stop-gap solution until vaccines and antiviral... by DarmokJalad1701 on Sunday March 22, 2020 @12:36AM (#22652764)
This may be a stupid question. But can the antibodies be synthesized based on samples from recovered patients? If not, why?
Re:Covid-19’s stop-gap solution until vaccines and antiviral... by whoisjuan on Sunday March 22, 2020 @01:03AM (#22652863)
Yes. Synthetic antibodies are a thing, but they are very expensive and very hard to produce (from what I inderstand).

Using animals when possible (for example horses, for the production of snake venom antidotes) seems more efficient in cost, volume and time.

Take for instance this crisis. They just need the plasma of immune individuals to give temporary immunity to sick or at risk individuals. It doesn’t scale but it works.

Some good basic reads:

Antigens - https://en.m.wikipedia.org/wiki/Antigen

Humoral Inmunity -https://en.m.wikipedia.org/wiki/Humoral_immunity

Synthetic antibodies -https://en.m.wikipedia.org/wiki/Synthetic_antibody

Antibodies memetic - https://en.m.wikipedia.org/wiki/Antibody_mimetic

Re:Covid-19’s stop-gap solution until vaccines and antiviral... by andreareina on Sunday March 22, 2020 @01:09AM (#22652884)
Protein synthesis is complicated. Antivenom is still produced in the same way: inject an animal with small doses of venom, collect the antibodies from the plasma.

[1] https://en.wikipedia.org/wiki/Antivenom

Re:Covid-19’s stop-gap solution until vaccines and antiviral... by snowmaker on Sunday March 22, 2020 @01:01AM (#22652848)
Yes, and there are companies working on exactly this. Abcellera is furthest along: https://www.fiercebiotech.com/biotech/lilly-taps-abcellera-t...
Re:Covid-19’s stop-gap solution until vaccines and antiviral... by ars on Sunday March 22, 2020 @01:27AM (#22652954)
That's basically what a https://en.wikipedia.org/wiki/Monoclonal_antibody is - and those are by far the most expensive drugs there are, with costs in the $100,000/person range.
Re:Covid-19’s stop-gap solution until vaccines and antiviral... by freepor on Sunday March 22, 2020 @03:30AM (#22653335)
What would the costs look like if the market scaled up by 1000 or 10000x?
Re:Covid-19’s stop-gap solution until vaccines and antiviral... by acqq on Sunday March 22, 2020 @03:39AM (#22653363)
The cost comes from the nonscalability of both the production and the use.
Re:Covid-19’s stop-gap solution until vaccines and antiviral... by jlokier on Sunday March 22, 2020 @04:49AM (#22653629)
What are the main obstacles to scalability of production and of use?

Could the former be amenable to treatment as an engineering problem? There are a lot of motivated engineering minds right now.

Re:Covid-19’s stop-gap solution until vaccines and antiviral... by acqq on Sunday March 22, 2020 @06:20AM (#22653961)
I'm not a professional in that area, just based on what I've read, so in case of doubt, check better sources:

If you use human donors, you need trained doctors spending time and equipment to select the donors, handle the donors, take care of them during the donation which takes hours (the needle is stuck in their vein during that time), trained professionals using expensive equipment to process the donation, and then trained doctors to perform the infusion on the patient, an hour or two, but you still want keep the patient in the hospital overnight in case of complications, which do happen often enough that it was practice to do so: as in, once in thousand. At the end all that work, it is relatively sure that the described work could result in protection of exactly one patient more than before you started. The percentage of known complications and the potential for failure in every step is what makes it non scalable.

With non human donors you can avoid some work, but the second part remains: it's not "just a shot" like when you do a vaccination which is scalable.

And while vaccination is scalable, if you're going to vaccinate billions, you also want to be very sure you aren't harming them, that's why speeding up vaccine production is not scalable. Even producing the vaccines is not easy at all to scale.

It's not that nobody has attempted hard to achieve this up to now.

Re:Covid-19’s stop-gap solution until vaccines and antiviral... by jlokier on Sunday March 22, 2020 @11:13PM (#22660929)
Thanks, that's quite informative.

In a critical situation such as the pandemic, it seems to me, from a project management and engineering perspective, that it might be worth ramping up production of a vaccine (or several) even before it has passed later stage trials, and maybe even pre-distribute it a bit to national storage facilities. So if the trials look great and the side effects are sufficiently minimal, the delay for manufacture and distribution will be reduced after the trials.

But I guess I see all sorts of political problems with that, if the trials are good but the side effects are a problem, or say it causes a horrible desease for 0.1% of people down the line. The pressure to use the product would be immense, despite the trial saying no this is not safe.

Re:Covid-19’s stop-gap solution until vaccines and antiviral... by acqq on Monday March 23, 2020 @04:23AM (#22662098)
Long term, THE major problem is the expectation to profit every time, stupidly, nobody with the money cares if one of that times the whole world gets infected:

https://www.newyorker.com/news/news-desk/how-long-will-it-ta...

"There may never be a market for a vaccine at the end of the development process, because the epidemic is contained, or never comes to pass. Then, traditionally, if there is an epidemic, it may take hold in a developing country where the costs of research and development cannot be recouped. “The resources and expertise sit in biotech and pharma, and they’ve got their business model,” Grant said. “They’re not charities. They can’t do this stuff for free.”"

The "investors" just want the growth of their money, even the money they make would become meaningless after the pandemics that's efficient enough. The nature is indeed capable to set its own growth not caring about the "interests of investors."

Obviously the whole structure as well as the priorities just have to be set differently. The next time could be even much worse than now.

Which must be a political decision for change, not a technological "invention". The technology is not a "deux ex machina" -- the natural limitations are real. Some solutions exist but simply can't be expected to "make profit every time." So how can it be done? Taxes. What was too dangerous selling point for generations of politicians? "Less taxes."

https://en.wikipedia.org/wiki/Deus_ex_machina

But the taxes are even now used, and spent in mind boggling amount, just for other priorities, year after year:

https://www.nytimes.com/2019/08/21/magazine/f35-joint-strike...

Re:Covid-19’s stop-gap solution until vaccines and antiviral... by boticus_prime on Sunday March 22, 2020 @01:02AM (#22652852)
https://www.fiercebiotech.com/research/fast-moving-regeneron...

>Regeneron scientists have isolated hundreds of neutralizing antibodies against the SARS-CoV-2 virus from a humanized mouse model as well as from humans who have recovered from COVID-19, the company said Tuesday.

Re:Covid-19’s stop-gap solution until vaccines and antiviral... by mtsr on Sunday March 22, 2020 @03:18AM (#22653303)
A monoclonal antibody (-mab) already existed in a lab in the Netherlands, because it had been developed for SARS and turned out to work for SARS-CoV-2. But it will take weeks before this can be industrialized, let alone approved.
Re:Covid-19’s stop-gap solution until vaccines and antiviral... by dnautics on Sunday March 22, 2020 @02:25PM (#22657242)
Not really in time.

In principle, yes, but antibodies are more complicated than normal molecules (glycosylation, protein folding) so you can really only industrially prepare them in certain types of cells (pretty much Chinese Hamster Ovary, last I checked).

Another problem is retrieving the correct antibody gene sequence. All immunoactive antibodies have been subjected to a process of internal evolution and artificial selection. Their DNA is not the same as your germline DNA, through shuffling and active mutation events, and indeed every immune cell that produces antibodies has different DNA than the other ones (that haven't been told to clone themselves) so it's really difficult to retrieve the correct gene sequence.

In practice I wouldn't estimate it to be possible to do this in the 4-6 month timeframe. Maybe in the 6-12 month timeframe under emergency duress situations.

Re:Covid-19’s stop-gap solution until vaccines and antiviral... by felipemnoa on Sunday March 22, 2020 @12:57AM (#22652826)
Following your train of thought, could the synthesis be done in the same way that insulin is currently created? i.e. Have some germs synthesize the antibodies.
Re:Covid-19’s stop-gap solution until vaccines and antiviral... by chispamed on Sunday March 22, 2020 @03:08AM (#22653291)
Yes, that’s a possibility and currently many monoclonal antibodies are produced that way (basically all drugs ending in “-mab”). However the process is costly and current capacities are not sufficient to supply a whole population regularly with antibodies which is why we still use some older drugs for certain diseases (think MTX for rheumatoid arthritis) and reserve monoclonal antibodies for treatment-resistant cases. I hope that it’ll be possible to protect high risk HCW and ICU patients through antibodies and thereby bring down Covid’s mortality soonish but we still need to buy some time until then and work on a vaccine to protect the population long-term. Right now what we need to do is stay at home and invest in medical care and drug development but with emphasis on the staying at home part because it’s the necessary condition for everything else to work.
Re:Covid-19’s stop-gap solution until vaccines and antiviral... by felipemnoa on Sunday March 22, 2020 @01:00PM (#22656464)
Thanks for your reply. Very informative.
Re:Covid-19’s stop-gap solution until vaccines and antiviral... by echelon on Sunday March 22, 2020 @02:48AM (#22653232)
You need to create a cell line.

Many medicines today use murine (mouse) monoclonal antibodies.

Re:Covid-19’s stop-gap solution until vaccines and antiviral... by jliptzin on Sunday March 22, 2020 @12:48AM (#22652798)
Definitely not a stupid question
Re:Covid-19’s stop-gap solution until vaccines and antiviral... by ethbro on Sunday March 22, 2020 @12:59AM (#22652840)
Not stupid. NOTE: Not my field, so speaking off basic knowledge here. Happy to be corrected.

Tl;dr: because biology at scale is complicated.

Longer-form, because antibodies and immunological response are somewhat complicated. Knowing what an antibody looks like, how to produce it, and how to scale that production in a safe and reliable way are all very different things.

Older article, but general concepts: http://neobiolab.com/research/in-vitro-and-in-vivo-productio...

... And because the in vivo methods we know of are ethically dicey. To rephrase it in rough terms -- creating custom cancers that produce the thing we want and giving them to mice, then harvesting concentrated antibodies from the tumors.

See: https://en.wikipedia.org/wiki/Hybridoma_technology